TransMedics Group Inc. reported strong financial results for the fourth quarter and full year of 2024. The company achieved total revenue of $121.6 million in Q4, marking a 50% increase compared to the same period in 2023. For the full year, total revenue reached $441.5 million, an 83% increase from 2023. The company also reported a net income of $6.9 million for Q4, with earnings per share (EPS) of $0.19, surpassing analysts' estimates of $0.16. Sales for the quarter exceeded expectations, coming in at $121.62 million against an estimate of $110.29 million. Additionally, the company's guidance for 2025 indicates projected sales of $541 million, higher than the anticipated $520 million. Following the earnings report, TransMedics' stock rose by 10% in after-hours trading.